Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
about
Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.Asparaginase pharmacology: challenges still to be faced.Advances in adult acute lymphoblastic leukemia therapy.Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional studyOutcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.Reactions related to asparaginase infusion in a 10-year retrospective cohort.Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins.Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase
P2860
Q33557148-DE88A10B-5C36-4420-9573-ABDCAA498EBDQ38880102-7A73D0C3-79B0-4706-8207-9192D3912E90Q38933372-84B98553-7C3C-489C-9AA3-191BCBE18A51Q38934988-8BD55337-6AE4-4076-9DA5-7DCF619AEB6DQ39135887-122BE791-DC5C-44D1-BC9C-CB199F040393Q39459190-A14A0678-6846-4367-BDA3-F800B10C7F91Q41491082-EDE5F995-DB60-484A-BB63-F52CF41641A8Q45873829-572153D6-25A0-4493-8DF4-173A3B1551F8Q47133515-D69D764A-B992-4B02-A4B7-F3F5F8681447Q48157639-B8E9BE59-3F2A-4ACF-B241-5881FD76F6BAQ48166631-CC315B83-831A-4F95-A548-B9A18AE09F88Q48353602-2E19C68B-D10D-4716-9D09-3EAA2F98DA35Q49818206-707CF6C9-8746-4259-AB40-FE87AFBB25FAQ50143850-145FD044-D128-4B58-823E-2C601393E16DQ52650744-0DDEC494-CF6F-48B6-9E47-C0491FD89EA7Q55340882-9AC36472-5FC2-465B-B44E-E29F3A430D10Q57201614-9FF92761-0258-46EF-9FE2-A6733890A926
P2860
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Consensus expert recommendatio ...... ivity and silent inactivation.
@en
type
label
Consensus expert recommendatio ...... ivity and silent inactivation.
@en
prefLabel
Consensus expert recommendatio ...... ivity and silent inactivation.
@en
P2093
P2860
P1433
P1476
Consensus expert recommendatio ...... ivity and silent inactivation.
@en
P2093
Andre Baruchel
Carmelo Rizzari
Inge M van der Sluis
James A Whitlock
Jose Sanchez de Toledo
Lewis B Silverman
Lynda M Vrooman
Nicholas Goulden
Veerle Mondelaers
P2860
P304
P356
10.3324/HAEMATOL.2015.137380
P577
2016-03-01T00:00:00Z